Diabetes drug trial needs to widen participants to understand full impact

More work needs to be done to examine the real world effects of the commonly prescribed diabetes drug empagliflozin, new research finds.

Examining data from over 60,000 patients with type 2 diabetes, researchers from the University of Surrey discovered that the highly-publicised cardiovascular benefits of the popular diabetes drug empagliflozin cannot be applied to the vast majority of patients with the illness.

Decreased heart attack risk

An international safety trial of empagliflozin, and other drugs in the sodium-glucose co-transporter 2 (SGLT2) inhibitor drug class, made the surprising discovery that these medications positively impact upon the workings of cardiovascular systems, including a decreased risk of heart attacks. Despite being hailed as ground-breaking, limitations of the trial were identified due to its focus on patients identified as high risk of cardiovascular disease.

Potential impact

Equipped with this knowledge, researchers from the University of Surrey examined the potential impact of this drug on those deemed at lower risk of cardiovascular disease. Researchers found that only 11% of patients with type 2 diabetes who were prescribed empagliflozin were identified as being at as high a risk of cardiovascular disease as those in the trial. They concluded that these patients may not see any cardiovascular improvements from the drug.

Similarly, only 16% of patients with type 2 diabetes who were not prescribed the drug were identified as being as high a risk of cardiovascular disease as those in the trial.

Such findings highlight the limitations of clinical trials which are often only directly applicable to a small proportion of people whom the medications are prescribed for and often leads to misconceptions about the workings of the drug.

“Recognising this shortcoming will help clinicians better explain to patients how this drug will benefit them.”